tbuckley/cabot-search huggingface dataset:
Impact of Extended Molecular RBC Antigen Matching between Blood Donors and Patients with Hematological Diseases
Authors: Bruno Ribeiro Cruz, Thamy Caroline S Silva, Elyse Moritz, Iara Rabelo, Bianca S Castro, Akemi Kuroda Chiba, Melca Oliveira Barros, Maria de Lourdes Chauffaille, Josefina Aparecida Pellegrino Braga, Maria Stella Figueiredo, Jose Orlando Bordin
Journal: Blood (2017)
Response to: ’Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki<i>et al'</i>by Wallace
Authors: Efrosini Papadaki, Antonis Fanouriakis, Eleftherios Kavroulakis, Dimitra Karageorgou, Prodromos Sidiropoulos, George Bertsias, Panagiotis Simos, Dimitrios T Boumpas
Journal: Annals of the Rheumatic Diseases (2018)

We thank Dr Wallace1 for his interest in our paper entitled ‘Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal appearing white matter in primary neuropsychiatric lupus erythematosus’ by Papadaki et al 2 and for giving us the opportunity to clarify aspects of our work. Our response to the points raised, follow next:

1.  American College of Rheumatology ( ACR) nomenclature . We do agree that this nomenclature, although useful, is indeed outdated and may need refinement and updating. In our study, the attribution of primary NPSLE …
Ataxia Telangiectasia–Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells
Authors: Lee Zou
Journal: Journal of Clinical Oncology (2018)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. December 18, 2017 ARTICLE CITATION DOI: 10.1200/JCO.2017.77.1857 Journal of Clinical Oncology - published online before print January 25, 2018 PMID: 29369707 Ataxia Telangiectasia–Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells Lee ZouxLee ZouSearch for articles by this author Show More Lee Zou, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA https://doi.org/10.1200/JCO.2017.77.1857 First Page Full Text PDF Figures and Tables © 2018 by American Society of Clinical Oncology Companion Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Inhibition of FLT3-ITD and Melk By Small Molecule Inhibitor OTS167 in FLT3 mutant Acute Myeloid Leukemia (AML)
Authors: Bartholomew Eisfelder, Houda Alachkar, Margaret Colton, Noreen Fulton, Olatoyosi Odenike, Yusuke Nakamura, Wendy Stock
Journal: Blood (2017)
Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies
Authors: Helena Edlund, Marilee Andrew, Feng Jin, Priti Patel, Eric Masson, J. Greg Slatter, Sergey Aksenov, Nidal Al-Huniti
Journal: Blood (2017)
Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Authors: Sheeba K. Thomas, Jatin J. Shah, Hans C. Lee, Elisabet E. Manasanch, Donna M. Weber, Krina K. Patel, Lei Feng, Behrang Amini, Ashley Morphey, Brandon Crumpton, Suzanne Phillips, Carla Miller, Mariann Gonzalez, Robert Z. Orlowski
Journal: Blood (2017)
Clinicopathological characteristics and prognostic factors of remnant gastric cancer: A single-center retrospective analysis of 90 patients
Authors: Xiao-Hai Song, Kai Liu, Li-Fei Sun, Xiao-Long Chen, Lin-Yong Zhao, Wei-Han Zhang, Xin-Zu Chen, Kun Yang, Bo Zhang, Zhi-Xin Chen, Jia-Ping Chen, Zong-Guang Zhou, Jian-Kun Hu
Journal: International Journal of Surgery (2018)
Effective Exercise Interventions for Patients and Survivors of Cancer Should be Supervised, Targeted, and Prescribed With Referrals From Oncologists and General Physicians
Authors: Robert U. Newton, Dennis R. Taaffe, Suzanne K. Chambers, Nigel Spry, Daniel A. Galvão
Journal: Journal of Clinical Oncology (2018)

TO THE EDITOR: We agree with Hardcastle and Cohen1 that physical activity is important for patients and survivors of cancer, and that the oncology specialist is ideally suited to promote this message. Indeed, a key strategy in cancer management is the increased awareness by medical and health professionals who support patients with cancer and survivors that physical activity and exercise is a critical component of patient care and a necessary intervention to improve health outcomes; however, the recommendations by Hardcastle and Cohen1 for implementation are an oversimplification that may adversely impact the integration of exercise medicine into best practice management of cancer.
Bosentan for Cutaneous Ulcers in Anti-MDA5 Dermatomyositis
Authors: Andrea Combalia, Priscila Giavedoni, Lorena Tamez, Josep M. Grau-Junyent, Jose M. Mascaró
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma
Authors: Sung Hee Kil, Renee Estephan, James Sanchez, Jasmine M. Zain, Marshall E. Kadin, James W. Young, Steven T. Rosen, Christiane Querfeld
Journal: Blood (2017)
Bmal1 in Perivascular Adipose Tissue Regulates Resting-Phase Blood Pressure Through Transcriptional Regulation of Angiotensinogen
Authors: Lin Chang, Wenhao Xiong, Xiangjie Zhao, Yanbo Fan, Yanhong Guo, Minerva Garcia-Barrio, Jifeng Zhang, Zhisheng Jiang, Jiandie D. Lin, Y. Eugene Chen
Journal: Circulation (2018)

The perivascular adipose tissue (PVAT) surrounding vessels constitutes a distinct functional integral layer of the vasculature required to preserve vascular tone under physiological conditions. However, there is little information on the relationship between PVAT and blood pressure regulation, including its potential contributions to circadian blood pressure variation.Using unique brown adipocyte-specific aryl hydrocarbon receptor nuclear translocator-like protein 1 (Bmal1) and angiotensinogen knockout mice, we determined the vasoactivity of homogenized PVAT in aortic rings and how brown adipocyte peripheral expression of Bmal1 and angiotensinogen in PVAT regulates the amplitude of diurnal change in blood pressure in mice.We uncovered a peripheral clock in PVAT and demonstrated that loss of Bmal1 in PVAT reduces blood pressure in mice during the resting phase, leading to a superdipper phenotype. PVAT extracts from wild-type mice significantly induced contractility of isolated aortic rings in vitro in an endothelium-independent manner. This property was impaired in PVAT from brown adipocyte-selective Bmal1-deficient (BA-Bmal1-KO) mice. The PVAT contractile properties were mediated by local angiotensin II, operating through angiotensin II type 1 receptor-dependent signaling in the isolated vessels and linked to PVAT circadian regulation of angiotensinogen. Indeed, angiotensinogen mRNA and angiotensin II levels in PVAT of BA-Bmal1-KO mice were significantly reduced. Systemic infusion of angiotensin II, in turn, reduced Bmal1 expression in PVAT while eliminating the hypotensive phenotype during the resting phase in BA-Bmal1-KO mice. Angiotensinogen, highly expressed in PVAT, shows circadian expression in PVAT, and selective deletion of angiotensinogen in brown adipocytes recapitulates the phenotype of selective deletion of Bmal1 in brown adipocytes. Furthermore, angiotensinogen is a transcriptional target of Bmal1 in PVAT.These data indicate that local Bmal1 in PVAT regulates angiotensinogen expression and the ensuing increase in angiotensin II, which acts on smooth muscle cells in the vessel walls to regulate vasoactivity and blood pressure in a circadian fashion during the resting phase. These findings will contribute to a better understanding of the cardiovascular complications of circadian disorders, alterations in the circadian dipping phenotype, and cross-talk between systemic and peripheral regulation of blood pressure.
Abstract DD01-04: NVP-BKM120: A selective inhibitor of type I PI3 kinases
Authors: William R. Sellers
Journal: Cancer Research (2010)

Abstract AACR 2010 - poster I Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials The PI3K/Akt/mTor signaling pathway plays an important role in controlling cell growth, proliferation and survival. Through various mechanisms, the pathway is frequently dysregulated in human cancers, suggesting the use of pathway modulators as novel targeted anticancer therapeutic agents. To this end, substantial drug discovery efforts have been devoted both in pharmaceutical companies and in academia to identify and develop therapeutic agents able to specifically down regulate this pathway in tumors cells. Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clinical compound, we sought to identify additional PI3K inhibitors from different chemical classes with more stringent selectivity profiles. The key to achieve these objectives was to pursue a structure-based design approach coupled with intensive pharmacological evaluation of selected compounds during the medicinal chemistry optimization process. Here we report on the biological characterization of the pan-PI3K pyrimidine-derived inhibitor NVP-BKM120. This compound inhibits all four Class I PI3K isoforms (IC50 values in the 35 to 248 nM range) with at least 50-fold selectivity (compared to p110[[Unsupported Character - Symbol Font ]]) towards protein kinases. The compound is also active against the most common somatic PI3K[[Unsupported Character - Symbol Font ]] mutations (H1047R, E542K and E545K). NVP-BKM120 does not significantly inhibit the related Class III (Vps34) and Class IV (mTOR, DNA-PK) PI3K kinases. Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic and relevant tumor cell lines (e.g., IC50 for S473P-Akt in Rat1-p110[[Unsupported Character - Symbol Font ]] cells of 93 nM). This biological activity correlates with inhibition of various Akt downstream signaling pathway components, and with its anti-proliferative activity. Thus, the compound demonstrates significant, concentration dependent cell growth inhibition and induction of apoptosis in a variety of tumor cancer cells, particularly for those harboring p110[[Unsupported Character - Symbol Font ]] mutants and/or over-expressing erbB2. In addition, NVP-BKM120 demonstrates significant, dose dependent in vivo pharmacodynamic activity as measured by inhibition of p-Akt in relevant xenograft models. The pharmacological, biological and preclinical safety profile of NVP-BKM120 supports its clinical development and the compound is currently undergoing Phase 1/II clinical trials in cancer patients. Citation Format: William R. Sellers. NVP-BKM120: A selective inhibitor of type I PI3 kinases [abstract]. In: Proceedings of the AACR 101st Annual Meeting 2010; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr DD01-04
Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram (vol 26, pg 1930, 2015)
Authors: B. Groot Koerkamp, J. K. Wiggers, M. Gonen, A. Doussot, P. J. Allen, M. G. H. Besselink, L. H. Blumgart, O. R. C. Busch, M. I. D'Angelica, R. P. DeMatteo, D. J. Gouma, T. P. Kingham, T. M. van Gulik, W. R. Jarnagin
Journal: Annals of Oncology (2016)
Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers
Authors: Kara A. Michels, Ruth M. Pfeiffer, Louise A. Brinton, Britton Trabert
Journal: JAMA Oncology (2018)

<h3>Importance</h3> Although oral contraceptive (OC) use is common, the influence of OC use on carcinogenesis is not fully understood. A recent Agency for Healthcare Research and Quality report identified a need to understand the consistency of OC use and cancer associations across subpopulations, including smokers and obese women. <h3>Objective</h3> To determine whether associations between duration of OC use and risk of specific cancers were modified by lifestyle characteristics. <h3>Design, Setting, and Participants</h3> The prospective NIH-AARP Diet and Health Study (enrolled 1995-1996, followed until 2011), with population-based recruitment of AARP members in 6 states and 2 metropolitan areas. All analyses included at least 100 000 women who reported OC use at enrollment. We identified 1241 ovarian, 2337 endometrial, 11 114 breast, and 3507 colorectal cancer cases during follow-up. Data analysis was performed between September 2016 and April 2017. <h3>Exposures</h3> Duration of OC use (never or &lt;1 year [reference], 1-4, 5-9, or ≥10 years). <h3>Main Outcomes and Measures</h3> Development of ovarian, endometrial, breast, and colorectal cancers. We examined effect modification by modifiable lifestyle characteristics: cigarette smoking, alcohol consumption, body mass index (BMI), and physical activity. We used Cox models adjusted for age, race, age at menarche, and the modifiers of interest. <h3>Results</h3> The analytic population was aged 50 to 71 years (median, 62 years) at enrollment and largely white (91%) and postmenopausal (96%). For ovarian cancer, OC use–associated risk reductions strengthened with duration of use (long-term OC use [≥10 years] HR, 0.60; 95% CI, 0.47-0.76;<i>P</i> &lt; .001 for trend) and were similar across modifiable lifestyle factors. Risk reductions for endometrial cancer strengthened with duration of use (long-term OC use HR, 0.66; 95% CI, 0.56-0.78;<i>P</i> &lt; .001 for trend); the most pronounced reductions were among long-term OC users who were smokers (HR, 0.47; 95% CI, 0.25-0.88), had obese BMIs (0.36; 95% CI, 0.25-0.52), and who exercised rarely (HR, 0.40; 95% CI, 0.29-0.56). Associations between OC use and breast and colorectal cancers were predominantly null. <h3>Conclusions and Relevance</h3> Long-term OC use is consistently associated with reduced ovarian cancer risk across lifestyle factors. We observed the greatest risk reductions for endometrial cancer among women at risk for chronic diseases (ie, smokers, obese BMI). Oral contraceptive use may be beneficial for chemoprevention for a range of women with differing baseline cancer risks.
Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance
Authors: Souvik Bhattacharjee, Isabelle Coppens, Alassane Mbengue, Niraja Suresh, Mehdi Ghorbal, Zdenek Slouka, Innocent Safeukui, Hsin-Yao Tang, David W. Speicher, Robert V. Stahelin, Narla Mohandas, Kasturi Haldar
Journal: Blood (2018)
Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis
Authors: Catriona T Prendergast, Agapitos Patakas, Shaima Al-Khabouri, Claire L McIntyre, Iain B McInnes, James M Brewer, Paul Garside, Robert A Benson
Journal: Annals of the Rheumatic Diseases (2018)

Objectives Successful early intervention in rheumatoid arthritis (RA) with the aim of resetting immunological tolerance requires a clearer understanding of how specificity, cellular kinetics and spatial behaviour shape the evolution of articular T cell responses. We aimed to define initial seeding of articular CD4 + T cell responses in early experimental arthritis, evaluating their dynamic behaviour and interactions with dendritic cells (DCs) in the inflamed articular environment. Methods Antigen-induced arthritis was used to model articular inflammation. Flow cytometry and PCR of T cell receptor (TCR) diversity genes allowed phenotypic analysis of infiltrating T cells. The dynamic interactions of T cells with joint residing DCs were visualised using intravital multiphoton microscopy. Results Initial recruitment of antigen-specific T cells into the joint was paralleled by accumulation of CD4 + T cells with diverse antigen-receptor expression and ability to produce tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) on mitogenic restimulation. A proportion of this infiltrate demonstrated slower motility speeds and engaged for longer periods with articular DCs in vivo. Abatacept treatment did not disrupt these interactions but did reduce T cell expression of inducible costimulatory (ICOS) molecule. We also demonstrated that non-specific CD4 + T cells could be recruited during these early articular events. Conclusions We demonstrate that CD4 + T cells engage with articular DCs supporting antigen specific T cell reactivation. This cellular dialogue can be targeted therapeutically to reduce local T cell activation.
Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis
Authors: Buket Yiğit, Marie Boyle, Oğuz Özler, Nihan Erden, Faik Tutucu, Timothy Hardy, Christina Bergmann, Joerg H W Distler, Gupse Adalı, Murat Dayangaç, Derek A Mann, Mujdat Zeybel, Jelena Mann
Journal: Gut (2018)

We recently reported dynamic epigenetic markers of fibrosis detectable in patients’ plasma that may have utility in non-invasive diagnosis and staging of fibrosis in patients with chronic liver disease.1 Specifically, we uncovered DNA methylation markers at the human PPARγ promoter detectable in circulating cell-free DNA (ccfDNA) that display differential methylation densities. Remarkably, PPARγ hypermethylation correlated with progression to cirrhosis in alcoholic liver disease (ALD) and with specific stages of liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Furthermore, ccfDNA signatures were traced back to the molecular pathology in fibrotic liver tissue, providing a biomarker of the underlying pathological process and defining hepatocytes as the source of hypermethylated DNA found in plasma.1 

The original study posed several important outstanding questions: (1) Can ccfDNA methylation be used as a biomarker of fibrosis in liver diseases of other aetiologies? (2) Does the presence of hepatocellular carcinoma (HCC) alter the biomarker in plasma? (3) Does presence of fibrosis in other organs generate similar biomarker profiles?

In the present letter, we answer these questions and demonstrate the broader utility of DNA methylation at three CpG dinucleotides within PPARγ promoter in several new patient cohorts (figure 1A and table …
Abstract P036: RBC Omega-3 Fatty Acids, Incident CVD and Total Mortality: Framingham Heart Study
Authors: William Harris, Nathan Tintle, Sander J Robins, Ramachandran S Vasan
Journal: Circulation (2017)

Background: The potential role of the marine omega-3 fatty acids (FA) EPA and DHA in cardiovascular disease (CVD) is unclear. Diet- and biomarker-based prospective studies have shown cardioprotective associations while several recent (relatively low dose, short term) randomized trials have shown no benefit. Methods: We examined CV outcomes and death in 2899 individuals in the Framingham Heart Study Offspring cohort (mean age 66 years, 54% women; 399 individuals had prior CVD) as a function of baseline levels of EPA+DHA in erythrocyte membranes (the Omega-3 Index). The latter is expressed as a % of total membrane FAs and is a validated surrogate for tissue EPA+DHA content. Clinical outcomes were monitored for up to 9.5 years (median follow up, 7.26 years). Cox proportional hazards models stratified by prior CVD were adjusted for a variety of demographic characteristics, clinical status and RBC omega-6 FA content. Results: There were 296 CV events, 157 CHD events, 116 ischemic strokes, 76 CVD deaths, and 362 deaths from all causes. A 1-SD higher Omega-3 Index was associated with significantly lower risks for total CVD (29%), ischemic stroke (39%), and total mortality (24%) (Table). In individuals in the bottom 20% of Omega-3 Index (vs. the top 20%, i.e., &lt;4.2% vs &gt;6.8%) risk was reduced by 44% for any CV event, by 65% for ischemic stroke, by 65% for CHD death, and by 53% for death from any cause (Table). Relations with these outcomes for EPA and DHA separately were weaker than for the combined metric but in the same direction. Conclusions: Higher circulating levels of the marine omega-3 fatty acid levels are associated with reduced risk for incident CVD and ischemic stroke and for death from CHD and all-causes. Evidence for a causal connection between omega-3 fatty acids and these outcomes must await the results of longer-term and/or higher-dose intervention studies that are currently in progress.
The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)
Authors: Elaine Y Chung, Filippo Spriano, Ivo Kwee, Sara Napoli, Chiara Tarantelli, Eugenio Gaudio, Luciano Cascione, Andrea Cavalli, Alberto Arribas, Andrea Rinaldi, Davide Rossi, Emanuele Zucca, Anastasios Stathis, Katti Jessen, Brian J Lannutti, Jeffrey Toretsky, Francesco Bertoni
Journal: Blood (2017)
Ensuring Timely Access to Quality Care for US Veterans
Authors: Jennifer Daley
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal